Thyrocare Technologies
NSE: THYROCAREBSE: 539871
₹ 493.40▼ 1.35 (−0.27%)28 Oct, 03:29 pm IST
- Market cap
- ₹ 7,394 Cr.
- P/E
- 40.8x
- P/B
- 12.83x
- 52-week range
- 342.55 – 662
- ROE
- 28%
- ROCE
- 35%
- Dividend yield
- 2%
- Debt / equity
- 0.09
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- NSE, BSE
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Thyrocare Technologies against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)40.8 against a typical 20.5: pricier than most peers (1st = cheapest).22nd of 34
- Sales growth+24.4% against a typical +19.1% from a year earlier.9th of 31
- Profit growth+34.2% against a typical +25.2% from a year earlier.8th of 24
- Share price, 3 months−14.7% against a typical −7.5%.24th of 33
- Size₹ 7,393.8 Cr. market value against a typical ₹ 83 Cr. (1st = largest).4th of 34
Research by Minerva Capital Research Solutions
Our research team's work on Thyrocare TechnologiesAlso covered in
Sector note · 27 Mar 2025 · Free
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results | Thyrocare Technologies Limited has informed the Exchange about Board Meeting to be held on Thursday, October 29, 2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the quarter and half year ended September 30, 2026 |
| 23 Jul 2026 | Financial Results | Thyrocare Technologies Limited has informed the Exchange about Board Meeting to be held on July 23, 2026 to inter-alia consider and approve the Unaudited Standalone and Consolidated Financial results of the Company for the quarter ended June 30, 2026 |
| 7 May 2026 | Financial Results/Dividend | Thyrocare Technologies Limited has informed the Exchange about Board Meeting to be held on Thursday, May 07, 2026 to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026, and to recommend the final dividend, if any, for the financial year 2025-26. |
| 28 Jan 2026 | Financial Results | Thyrocare Technologies Limited has informed that the Board Meeting is scheduled to be held on January 28, 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025 |
| 14 Oct 2025 | Financial Results/Dividend/Bonus | To consider and approve the Unaudited financial results for quarter and half year ended September 30, 2025, Declaration of an Interim Dividend and Proposal for issue of bonus shares. |
| 23 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 23 Apr 2025 | Financial Results/Dividend | To consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025, and to recommend the final dividend, if any, for the financial year 2024-25. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 135 | 154 | 157 | 177 | 166 | 187 | 193 | 217 | 196 | 224 | 240 |
| Expenses | 110 | 103 | 121 | 115 | 129 | 124 | 130 | 135 | 145 | 138 | 149 | 163 |
| Operating Profit | 38 | 32 | 34 | 42 | 48 | 42 | 57 | 58 | 71 | 58 | 75 | 77 |
| OPM % | 25% | 23% | 22% | 27% | 27% | 25% | 30% | 30% | 33% | 30% | 34% | 32% |
| Other Income | 3 | 3 | 3 | 4 | 3 | 4 | 5 | 5 | 3 | −1 | 5 | 5 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 |
| Depreciation | 11 | 13 | 13 | 11 | 13 | 17 | 14 | 11 | 12 | 22 | 14 | 12 |
| Profit before tax | 28 | 20 | 23 | 34 | 37 | 28 | 47 | 50 | 63 | 35 | 64 | 68 |
| Tax % | 28% | 26% | 25% | 29% | 28% | 32% | 54% | 24% | 24% | 21% | 24% | 25% |
| Net Profit | 20 | 15 | 17 | 24 | 26 | 19 | 22 | 38 | 48 | 28 | 49 | 51 |
| EPS in Rs | 1.28 | 0.97 | 1.12 | 1.52 | 1.68 | 1.2 | 1.36 | 2.45 | 3.02 | 1.82 | 2.96 | 3.28 |
Growth and returns
Compounded yearly rates over each period.
Compounded Sales Growth
- 10 Years
- 13%
- 5 Years
- 11%
- 3 Years
- 16%
- TTM
- 21%
Compounded Profit Growth
- 10 Years
- 12%
- 5 Years
- 8%
- 3 Years
- 36%
- TTM
- 70%
Stock Price CAGR
- 10 Years
- 12%
- 5 Years
- 6%
- 3 Years
- 47%
- TTM
- —
Return on Equity
- 10 Years
- 21%
- 5 Years
- 20%
- 3 Years
- 20%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
P/E 40.8xEPS (12 months) ₹ 11.36Median P/E 47.1x
P/E (times)EPS (₹)
Prices are delayed and for information only. Nothing on this page is investment advice.